Who owns Apogee Therapeutics, Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
Fairmount Funds Management LLC: 0.0% · 0 shares — Fairmount Healthcare Fund II L.P.: 0.0% · 0 shares — Peter Evan Harwin: 0.0% · 0 shares
Wellington Management Group LLP: 0.9% · 564,326 shares — Wellington Group Holdings LLP: 0.9% · 564,326 shares — Wellington Investment Advisors Holdings LLP: 0.9% · 564,326 shares
6 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Apogee Therapeutics, Inc..
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Apogee Therapeutics, Inc. they hold. Together these 361 managers report 108.12% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| Venrock Adviser, LLC | $1.13B | 8,493,321 | 34.18% | 11.26% | June 30, 2026 |
| BlackRock, Inc. | $731M | 5,507,032 | 0.01% | 7.30% | June 30, 2026 |
359 more institutional holders behind a free account
See every manager reporting Apogee Therapeutics, Inc., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 329 funds hold 42.71% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund | $446M | 0.67% | 7.02% | March 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | $248M | 0.01% | 2.48% | June 30, 2026 |
327 more funds behind a free account
See every fund holding Apogee Therapeutics, Inc. and what share of its net assets the position represents.
Sign up freeLoading...
